Quitline Coaching Helps Young Adults Stop Vaping
By Lori Solomon HealthDay Reporter
MONDAY, Dec. 16, 2024 -- Almost half of young adults who vape are able to stop with quitline help, according to a study published online Dec. 11 in the American Journal of Preventive Medicine.
Katrina A. Vickerman, Ph.D., from RVO Health in Fort Mill, South Carolina, and colleagues randomly assigned 508 young U.S. adults (aged 18 to 24 years) who exclusively and regularly (20 or more days of the last 30) used e-cigarettes and were interested in quitting to mailed nicotine replacement therapy (NRT; eight weeks versus none) and/or mHealth (yes versus no; stand-alone text program including links to videos and online content) in the context of an active control of a two-call quitline coaching program.
The researchers found that in intent-to-treat seven-day point prevalence abstinence rates (missing assumed vaping) were 41 percent for those receiving calls only, 43 percent for calls plus mHealth, 48 percent for calls plus NRT, and 48 percent for calls plus NRT plus mHealth. No statistically significant differences were detected for mailed NRT (versus no mailed NRT) or mHealth (versus no mHealth).
"This quitline-delivered intervention was successful at helping young adults quit vaping, with almost half abstinent after three months," the authors write. "Higher than anticipated quit rates reduced power to identify significant group differences."
Several authors disclosed being employed by RVO Health, the provider of quitline cessation services in the randomized trial.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-12-17 06:00
Read more
- Panel of Biomarkers Can Distinguish Stable, Exacerbation States in COPD
- 'Brain Boost' From Today's Exercise May Linger Through Tomorrow
- Gabapentinoid Use Tied to Higher Risk for Hip Fractures
- Flu, COVID Vaccination Rates Remain Low as Winter Nears
- Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza
- California Child Tests Positive for Bird Flu
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions